DYAI Pengajuan SEC - Dyadic International, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1213809

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dyadic International, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 13, 2025	EX-99.1	Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress Exhibit 99.1 Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ● Completed Strategic Leadership and Operational Transformation from R&D to Commercial Operations ● Rebranded as Dyadic Applied BioSolutions to Reflect Our New Operational Priorities ● Full Redesign of Corporate Website to Prioritize Commercial Execution and Long-term Value Creation ● Comple
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32513 DYADIC INTERN
August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 13, 2025 Dyadic Internatio UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 13, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32513 45-0486747 (State or other jurisdiction of incorporation or organi
August 1, 2025	EX-99.2	Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock Exhibit 99.2 Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock JUPITER, Fla., July 31, 2025 — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industr
August 1, 2025	EX-1.1	Underwriting Agreement, dated July 30, 2025, by and between Dyadic International, Inc. and Craig-Hallum Capital Group LLC, in its capacity as underwriter Exhibit 1.1 DYADIC INTERNATIONAL, INC. 6,052,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement July 30, 2025 CRAIG-HALLUM CAPITAL GROUP LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions, a Delaware corporation (the “Company”), proposes to issue and sell to Craig-Hallum C
August 1, 2025	EX-99.1	Dyadic International, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Dyadic International, Inc. Announces Proposed Public Offering of Common Stock JUPITER, Fla., July 30, 2025 — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology appl
August 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2025 Dyadic Internationa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32513 45-0486747 (State or other jurisdiction of incorporation or organiza
July 31, 2025	424B5	DYADIC INTERNATIONAL, INC. 6,052,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273829 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 25, 2023) DYADIC INTERNATIONAL, INC. 6,052,000 Shares of Common Stock We are offering 6,052,000 shares of our common stock, par value $0.001 per share, at a price to the public of $0.95 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “DYAI.” On July 29,
July 30, 2025	424B5	SUBJECT TO COMPLETION, DATED July 30, 2025 The information in this preliminary prospectus supplement is not complete and may be changed.
July 23, 2025	EX-99.1	Dyadic International Presentation, “Precision engineered recombinant protein production that redefines performance, scalability and economy”, dated July 23 2025 Exhibit 99.1
July 23, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32513 45-0486747 (State or other jurisdiction of incorporation or organiza
July 23, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 23, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32513 45-0486747 (State or other jurisdiction of incorporation or organiza
July 2, 2025	EX-99.1	Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions Exhibit 99.1 Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla., July 2 , 2025 — Dyadic International, Inc. (“Dyadic”) (Nasdaq: DYAI), a global biotechnology company focused on the scalab
July 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 2, 2025 Dyadic International UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 2, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organizat
June 27, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 23, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organiza
June 24, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 20, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
June 2, 2025	EX-99.1	Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications Exhibit 99.1 Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications ● Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets ● Leadership team realigned in order to enable execution of ancillary protein strategy ● Dyadic is we
June 2, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 29, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or or
June 2, 2025	EX-3.2	Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025 (marked). Exhibit 3.2 THIRDFOURTH AMENDED AND RESTATED BYLAWS OF DYADIC INTERNATIONAL, INC. (A DELAWARE CORPORATION) EFFECTIVE AS OF MARCH 28MAY 29, 20232025 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Registered Office 1 Section 1.02 Other Offices 1 ARTICLE II STOCKHOLDERS' MEETINGS 1 Section 2.01 Place of Meetings 1 Section 2.02 Annual Meetings 1 Section 2.03 Special Meetings 3 Section 2.04 No
June 2, 2025	EX-3.1	Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025 Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF DYADIC INTERNATIONAL, INC. (A DELAWARE CORPORATION) EFFECTIVE AS OF MAY 29, 2025 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Registered Office 1 Section 1.02 Other Offices 1 ARTICLE II STOCKHOLDERS' MEETINGS 1 Section 2.01 Place of Meetings 1 Section 2.02 Annual Meetings 1 Section 2.03 Special Meetings 3 Section 2.04 Notice of Meetings
May 14, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
May 14, 2025	EX-99.1	Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress Exhibit 99.1 Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress ● Expanded life science and industrial portfolio with six additional life science products in development ● Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets ● Up to $4.5 million research grant awarded from the
May 5, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 1, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organizati
May 5, 2025	EX-4.1	Second Amendment to Form of Senior Secured Convertible Promissory Note due March 8,2027 Exhibit 4.1 SECOND AMENDMENT TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE MARCH 8, 2027 This Second Amendment (this “Amendment”), dated as of May 1, 2025, to that certain Senior Secured Convertible Promissory Note Due March 8, 2027 issued to the holder set forth on the signature page hereto (the “Holder”) on March 8, 2024 (the “Note”), is entered into by and among Dyadic International, Inc. (
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 29, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 28, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 31, 2025	CORRESP	March 31, 2025 March 31, 2025 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Dyadic International, Inc. (CIK No. 0001213809) Registration Statement on Form S-3 File No. 333-286121 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dyadic Inte
March 26, 2025	10-K	Form 10-K for the year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 26, 2025	S-3	As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.
March 26, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 DYADIC INTERNATIONAL, INC. Procedures And Guidelines Governing Insider Trading And Tipping I. Purpose In order to comply with federal and state securities laws governing (a) trading in Company securities while in the possession of “material non-public information” concerning the Company, and (b) tipping or disclosing material non-public information to outsiders, and in order to, among
March 26, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 26, 2025	EX-21.1	EX-21.1 Exhibit 21.1
March 26, 2025	EX-10.21	Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan Exhibit 10.2.1 DYADIC INTERNATIONAL, INC. 2021 EQUITY INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Dyadic International, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Equity Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the Holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par v
March 26, 2025	EX-99.1	DYADIC REPORTS 2024 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATES Exhibit 99.1 DYADIC REPORTS 2024 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATES ● Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 ● Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower cost ● Growth in
March 26, 2025	EX-10.22	Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan Exhibit 10.2.2 DYADIC INTERNATIONAL, INC. 2021 EQUITY INCENTIVE AWARD PLAN Restricted Stock Unit Award Grant Notice Dyadic International, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the Holder named below a Restricted Stock Unit Award (the “Award”) for the number of restricted stock units (“Restricted Stock Units”) set fo
March 26, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dyadic International, Inc.
March 20, 2025	EX-99.1	Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines Exhibit 99.1 Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines JUPITER, FL / March 20, 2025 (GLOBAL NEWSWIRE) Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for
March 20, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 20, 2025 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organiz
November 26, 2024	EX-99.1	Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Exhibit 99.1 Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Jupiter, FL, November 21, 2024 – Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3
November 26, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 16, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or orga
November 26, 2024	EX-10.1	Grant Agreement between Dyadic International, Inc. and the Bill & Melinda Gates Foundation, dated as of November 16, 2024 Certain identified information in this exhibit has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.
November 12, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organ
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC I
November 12, 2024	EX-99.1	Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Exhibit 99.1 Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins ● Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments. ● Received $1 m
November 12, 2024	EX-10.1	Employment Agreement dated November 8, 2024, between Dyadic International, Inc. and Ping Rawson EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 8th day of November 2024 (the “Effective Date”), by and between DYADIC INTERNATIONAL, INC.
October 8, 2024	EX-4.1	Amendment to Form of Senior Secured Convertible Promissory Note due March 8, 2027 Exhibit 4.1 AMENDMENT TO FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE MARCH 8, 2027 This Amendment (this “Amendment”), dated as of October 4, 2024, to that certain Senior Secured Convertible Promissory Note Due March 8, 2027 issued to the holder set forth on the signature page hereto (the “Holder”) on March 8, 2024 (the “Note”), is entered into by and among Dyadic International, Inc. (th
October 8, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 4, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or organi
August 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 13, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
August 13, 2024	EX-99.1	Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress Alternative Proteins ● Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals ● Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal a
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTERN
July 2, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 27, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
July 2, 2024	EX-99.1	Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership Exhibit 99.1 Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership Jupiter, FL, June 28, 2024 (Globe Newswire) - Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading sup
July 2, 2024	EX-10.1	License and Development Agreement between Dyadic International, Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024. Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]”. LICENSE AND DEVELOPMENT AGREEMENT This LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the date of last
July 2, 2024	EX-10.1	License and Development Agreement between Dyadic International, Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024. Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]”. LICENSE AND DEVELOPMENT AGREEMENT This LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the date of last
July 2, 2024	EX-99.1	Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership Exhibit 99.1 Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership Jupiter, FL, June 28, 2024 (Globe Newswire) - Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading sup
July 2, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 27, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
June 11, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 11, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
May 14, 2024	EX-99.1	Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Human Health Sector ● Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infection ● Entered i
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
May 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 3, 2024	CORRESP	May 3, 2024 May 3, 2024 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Dyadic International, Inc. (CIK No. 0001213809) Registration Statement on Form S-3 File No. 333-278916 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dyadic Interna
April 24, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 24, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 24, 2024	S-3	As filed with the Securities and Exchange Commission on April 24, 2024 As filed with the Securities and Exchange Commission on April 24, 2024 Registration No.
April 24, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dyadic International, Inc.
March 28, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1
March 28, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 28, 2024	EX-99.1	DYADIC REPORTS 2023 FULL YEAR RESULTS AND RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC REPORTS 2023 FULL YEAR RESULTS AND RECENT COMPANY PROGRESS ● Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants ● Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidat
March 28, 2024	EX-10.22	Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan Exhibit 10.2.2 DYADIC INTERNATIONAL, INC. 2021 EQUITY INCENTIVE AWARD PLAN Restricted Stock Unit Award Grant Notice Dyadic International, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the Holder named below a Restricted Stock Unit Award (the “Award”) for the number of restricted stock units (“Restricted Stock Units”) set fo
March 28, 2024	EX-97	Policy Related to Recovery of Erroneously Awarded Compensation Exhibit 97 Dyadic International, Inc POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION A.
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 28, 2024	EX-10.21	Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan Exhibit 10.2.1 DYADIC INTERNATIONAL, INC. 2021 EQUITY INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Dyadic International, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Equity Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the Holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par v
March 28, 2024	EX-99.2	Dyadic Announces Change in Board and Management Leadership Roles Exhibit 99.2 Dyadic Announces Change in Board and Management Leadership Roles JUPITER, FL – March 28, 2024 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applicatio
March 11, 2024	EX-10.2	Registration Rights Agreement, dated as of March 8, 2024, by and among the Registrant and the purchasers party thereto Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 8, 2024, by and among Dyadic International, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to that certain Securities Purchase A
March 11, 2024	EX-10.3	Security Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 Exhibit 10.3 SECURITY AGREEMENT SECURITY AGREEMENT, dated March 8, 2024, by and between Dyadic International, Inc., a Delaware corporation, with headquarters located at 1044 North U.S. Highway One, Suite 201, Jupiter, Florida 33477 (the “Debtor”), and the investors set forth on Schedule A hereof (collectively, the “Secured Party”). Debtor hereby agrees in favor of Secured Party as follows: 1. In c
March 11, 2024	EX-99.1	Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization Exhibit 99.1 Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization Jupiter, FL, March 11, 2024 - Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global pro
March 11, 2024	EX-4.1	Form of Senior Secured Convertible Promissory Note due March 8, 2027 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 11, 2024	EX-10.1	Securities Purchase Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 8, 2024, by and among Dyadic International, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and, collectively, the “Purchasers”). RECITALS A. The Company and each Purc
March 11, 2024	EX-10.4	Subsidiary Guarantee Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 Exhibit 10.4 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of March 8, 2024 (this “Guarantee”), made by each signatory hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of the purchaser signatory (each, including its successors and assigns, a “Purchaser” and, collectively, the “Purchasers”) to that certain Securities Purchas
March 11, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2024 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation or (Commiss
February 13, 2024	SC 13G/A	DYAI / Dyadic International, Inc. / Bandera Partners LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga208706dyai02142024.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Dyadic International, Inc. (Name of Issuer) Common Stock, $0.0
February 1, 2024	SC 13G/A	DYAI / Dyadic International, Inc. / Francisco Trust under agreement dated February 28, 1996 Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dyadic International, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) Thomas Emalfarb, Trustee 3128 San Michele Drive Palm Beach Gardens, FL 33418 (561) 430-7887 (Name
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC I
November 8, 2023	EX-99.1	Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress ● Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products ● DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 ● New research collaboration with Vaccine and Immunotherapy
November 8, 2023	EX-10.1	Lease Agreement with Jupiter Harbour Office, LLC dated August 19, 2023 Exhibit 10.1 LEASE AGREEMENT BETWEEN JUPITER HARBOUR OFFICE, LLC and DYADIC INTERNATIONAL (USA), INC. TABLE OF CONTENTS 1. Executive Summary of Lease Tenns 3 2. Premises 6 3. Term 7 4. Condition and Use of Premises 7 5. Rent 8 6. Tenant Financials 8 7. Improvements 8 8. Alterations. Additions and Improvements 8 9. Services 9 10. Access 9 11. Parking 9 12. Repairs 9 13. Liability 10 14. Taxes and A
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
November 8, 2023	EX-10.2	Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017 Exhibit 10.2 [*] indicates that certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential, pursuant to Item 601(b)(10) of Regulation S-K. SERVICE FRAMEWORK AGREEMENT This SERVICE FRAMEWORK AGREEMENT (this "Agreement"), signed as of June 30, 2017, is entered into by and between DYADIC INTER
October 6, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 5, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
October 6, 2023	EX-99.1	Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Exhibit 99.1 Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases JUPITER, FL / October 5, 2023, Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”
October 6, 2023	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation) (Commiss
September 19, 2023	EX-10.1	Inzyme Development and Exclusive License Agreement, effective September 18, 2023 Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]”. DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT This DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is made as of Septembe
September 19, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 18, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264
September 19, 2023	EX-99.1	Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using DapibusTM Exhibit 99.1 Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using DapibusTM ● Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, FL / September 19, 2023 Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, o
August 23, 2023	CORRESP	August 23, 2023 August 23, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.
August 9, 2023	S-3	As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.
August 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dyadic International, Inc.
August 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2023 Dyadic Internation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTERN
August 9, 2023	EX-99.1	Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress ● Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines ● Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh ● Progress in developing animal-free recombinant serum albumin with ini
June 15, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 9, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 9, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizat
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 9, 2023 Dyadic Internationa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 9, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2023 Dyadic International UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 10, 2023	EX-99.1	Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress ● New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human health ● Expanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for A
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 12, 2023	EX-99.1	Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent Exhibit 99.1 Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent JUPITER, FL (GLOBE NEWSWIRE) April 12, 2023 - Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand
April 12, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 6, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
April 12, 2023	EX-10.1	RUBIC License Agreement dated April 6, 2023 Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]”. LICENCING AGREEMENT This Licensing Agreement (the “Agreement”) is a binding agreement entered into as of April 6, 2023 (the “Effe
April 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 Dyadic Internation UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation) (Commissi
March 29, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 29, 2023	EX-99.1	DYADIC REPORTS 2022 YEAR END RESULTS AND RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC REPORTS 2022 YEAR END RESULTS AND RECENT COMPANY PROGRESS ● Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing grou
March 29, 2023	EX-10.111	Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated August 29, 2022 Exhibit 10.11.1 INTRACOASTAL POINTE OFFICE BUILDING AMENDMENT TO OFFICE LEASE This Amendment to Office Lease Agreement made and entered in to this 29th day of August, 2022 by and between Quentin Partners Co. as Agent for Intracoastal Pointe, Inc. (both Florida corporations), as “Landlord;” and Dyadic International, Inc., as “Tenant.” WITNESSETH WHEREAS, Landlord and Tenant entered into that Office
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 29, 2023 Dyadic Internation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 29, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 29, 2023	EX-3.1	Third Amended and Restated Bylaws dated March 28, 2023 Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF DYADIC INTERNATIONAL, INC. (A DELAWARE CORPORATION) EFFECTIVE AS OF MARCH 28, 2023 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Registered Office 1 Section 1.02 Other Offices 1 ARTICLE II STOCKHOLDERS' MEETINGS 1 Section 2.01 Place of Meetings 1 Section 2.02 Annual Meetings 1 Section 2.03 Special Meetings 3 Section 2.04 Notice of Meetings
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Dyadic Internation -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55264 45-0486747 (State or other jurisdiction of incorporation) (C
March 14, 2023	SC 13G/A	DYAI / Dyadic International Inc., DE / Francisco Trust under agreement dated February 28, 1996 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dyadic International, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) Adam J. Morgan, Trustee 3128 San Michele Drive Palm Beach Gardens, FL 33418 (561) 430-7887 (Name, Address and Telephone Num
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2023 Dyadic Internationa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
March 7, 2023	EX-99.1	Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate Exhibit 99.1 Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate ■ Dosing of all patients was completed at the end of February ■ No Serious Adverse Events (SAE’s) have been reported ■ Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 7, 2023 (GLOBE NEWSWIRE) - Dyadic Internati
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2023 Dyadic Internat UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
February 22, 2023	EX-16.1	Letter from Mayer Hoffman McCann P.C. to the U.S. Securities and Exchange Commission dated February 21, 2023
February 14, 2023	SC 13G/A	DYAI / Dyadic International, Inc. / EMALFARB MARK A - SCHEDULE 13G/A Passive Investment SC 13G/A 1 emalf20230212sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* DYADIC INTERNATIONAL, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the app
February 13, 2023	SC 13G/A	DYAI / Dyadic International, Inc. / Bandera Partners LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Dyadic International, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) Decembe
January 24, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
January 24, 2023	EX-99.1	Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate Exhibit 99.1 Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate JUPITER, FL / January 24, 2023, Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovati
January 23, 2023	EX-10.1	Alphazyme Sale Agreement dated January 18, 2023 Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]”. SECURITIES PURCHASE AGREEMENT by and among M A R A V A I L IF E S C I E N C E S H O L D I N G S, I N C., ALPHAZYME, LLC, SELLERS,
January 23, 2023	EX-99.1	Dyadic Announces Sale of Equity Interest in Alphazyme Exhibit 99.1 Dyadic Announces Sale of Equity Interest in Alphazyme JUPITER, FL., January, 19, 2023 (GLOBE NEWSWIRE) - Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceuti
January 23, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 18, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
January 4, 2023	EX-99.1	Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Fr EX-99.1 2 ex460691.htm EXHIBIT 99.1 Exhibit 99.1 Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USA JUPITER, FL / GLOBE NEWSWIRE / January 4, 2023, Dyadic International, Inc. (“Dyadic”,
January 4, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : January 4, 2023 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
January 4, 2023	EX-99.2	Dyadic International Presentation, “Next Generation Proteins for World Health”, dated January 4, 2023 Exhibit 99.2
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC I
November 10, 2022	EX-99.1	Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments Exhibit 99.1 Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments ? Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate ? Presented safety, effi
October 27, 2022	EX-99.1	Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate Exhibit 99.1 Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate JUPITER, FL / October 27, 2022, Dyadic International, Inc. (?Dyadic?, ?we?, ?us?, ?our?, or the ?Company?) (NASDAQ: DYAI), a global biotechnology company focused on building innovative micro
October 27, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 27, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
September 13, 2022	EX-99.2	Dyadic International Presentation, “Rapid, efficient low-cost monoclonal antibody production for LMICs”, dated September 13, 2022 Exhibit 99.2
September 13, 2022	EX-99.1	Dyadic Updates Market On Recent Scientific Achievements Exhibit 99.1 Dyadic Updates Market On Recent Scientific Achievements JUPITER, FL / GLOBE NEWSWIRE / September 13, 2022 Dyadic International, Inc. (?Dyadic?, or the ?Company?) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceut
September 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : September 13, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTERN
August 10, 2022	EX-99.1	Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments Exhibit 99.1 Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments ● Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate preliminary efficacy of DYAI-1
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
June 13, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 10, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
May 12, 2022	EX-99.1	Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments Exhibit 99.1 Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments ? New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic?s proprietary biotechnologies ? License agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s) ? Advancing first-in-human clinical trial application (CTA)
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
May 11, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 11, 2022	EX-99.1	Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients Exhibit 99.1 Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients JUPITER, FL / May 11, 2022, Dyadic International, Inc. (?Dyadic?, ?we?, ?us?, ?our?, or the ?Company?) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary protein production platform, today announced that it has entered in
May 11, 2022	EX-10.1	Joint Development Agreement dated May 10, 2022 Exhibit 10.1 Confidential Execution Version Confidential Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]?. JOINT DEVELOPMENT AGREEMENT This Joint Development Agreement (the ?Agreement? or ?JDA
April 26, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 22, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
April 26, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
April 26, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
April 13, 2022	EX-99.1	Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform Exhibit 99.1 Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic?s Licensed C1 Protein Production Platform ? India?s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-Cov-2 antigen ? Funding earmarked to support Phase 1 and 2 clinical trials of Epygen?s COVID-19 vaccine candidate ? Dyadi
April 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 13, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 29, 2022	EX-10.121	Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated August 13, 2021 Exhibit 10.12.1 INTRACOASTAL POINTE OFFICE BUILDING AMENDMENT TO OFFICE LEASE This Amendment to Office Lease Agreement made and entered in to this 16th day of August, 2021 by and between Quentin Partners Co. as Agent for Intracoastal Pointe, Inc. (both Florida corporations), as ?Landlord;? and Dyadic International, Inc., as ?Tenant.? WITNESSETH WHEREAS, Landlord and Tenant entered into that Office
March 29, 2022	EX-99.1	DYADIC REPORTS 2021 YEAR END RESULTS AND RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC REPORTS 2021 YEAR END RESULTS AND RECENT COMPANY PROGRESS ? New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteins ? Received NIIMBL coronavirus grant of $690,000 under the White House?s American Rescue Plan ? New license agreement with Phibro Animal Health to develop and commercialize certain animal health vac
March 29, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 29, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 29, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 18, 2022	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March17, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
February 28, 2022	SC 13G	DYAI / Dyadic International, Inc. / Francisco Trust under agreement dated February 28, 1996 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dyadic International, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) Adam J. Morgan, Trustee 3128 San Michele Drive Palm Beach Gardens, FL 33418 (561) 430-7887 (Name, Address and Telephone Numb
February 14, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2022 with respect to the Common Stock, $0.001 par value per share, of Dyadic International, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13
February 14, 2022	SC 13G	DYAI / Dyadic International, Inc. / Bandera Partners LLC - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Dyadic International, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) December
February 14, 2022	SC 13G/A	DYAI / Dyadic International, Inc. / EMALFARB MARK A - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DYADIC INTERNATIONAL, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 26745T101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 10, 2022	EX-99.1	Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine Exhibit 99.1 Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine ? The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease. JUPITER, FL February 10, 2022, Dyadic Internationa
February 10, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2022 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
December 17, 2021	EX-99.1	Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform Exhibit 99.1 Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform JUPITER, FL / December 17, 2021, Dyadic International, Inc. (?Dyadic?, ?we?, ?us?, ?our?, or the ?Company?) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell pr
December 17, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 16, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
December 17, 2021	EX-10.1	Research, License, and Collaboration Agreement with Janssen dated December 16, 2021 Exhibit 10.1 Confidential Execution Version Confidential Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]?. RESEARCH, LICENSE, AND COLLABORATION AGREEMENT between DYADIC INTERNATIONAL INC. and
December 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) :November 29, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
December 2, 2021	EX-99.1	Dyadic International Presentation, “C1 Technology Platform: Rapid response to Pandemic and other biological threats - Support the global combat against SARS-CoV-2 Variants of Concern”, dated November 29, 2021 Exhibit 99.1
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC I
November 10, 2021	EX-99.1	Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress ? COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption ? Five non-COVID-19 infectious disease monoclonal antibody and antigen development programs ar
November 9, 2021	EX-10.1	Employment Agreement between Dyadic International Inc. and Joseph Hazelton dated November 9, 2021 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into as of the 1st day of November 2021, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation, with its principal place of business at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477 (the ?Company?), and JOSEPH HAZELTON (?Employee?) (the Company and Employee are sometimes her
November 9, 2021	EX-99.1	Dyadic Appoints Chief Business Officer to Executive Leadership Team Exhibit 99.1 Dyadic Appoints Chief Business Officer to Executive Leadership Team JUPITER, FL / November 9, 2021 Dyadic International, Inc. (?Dyadic?, ?we?, ?us?, ?our?, or the ?Company?) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve
November 9, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
October 18, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 18, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
August 12, 2021	EX-99.1	Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Exhibit 99.1 Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress ? Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic?s lead COVID-19
August 12, 2021	S-8	Dyadic International, Inc. 2021 Equity Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 DYADIC INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-0486747 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 140 Intracoastal Pointe Drive, Suite 404 Jupiter, Florida (Address of Principal Executive Offices) 33477 (Zip Code) D
August 12, 2021	S-8 POS	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 for Dyadic International, Inc. 2006 Stock Option Plan, Dyadic International, Inc. 2011 Equity Incentive Plan, and Dyadic International, Inc. 2021 Equity Incentive Plan Registration No. 333-231712 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 DYADIC INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-0486747 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 140 Intracoastal Pointe Drive, Suite 404 Jupiter, Flori
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTERN
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 12, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
August 11, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
August 11, 2021	EX-99.1	DYADIC AND SORRENTO ANNOUNCE BINDING TERM SHEET TO LICENSE DYADIC’S LEAD COVID-19 VACCINE CANDIDATE “DYAI-100” AND C1 TECHNOLOGY FOR PROTEIN-BASED CORONAVIRUS VACCINES AND THERAPEUTICS Exhibit 99.1 DYADIC AND SORRENTO ANNOUNCE BINDING TERM SHEET TO LICENSE DYADIC?S LEAD COVID-19 VACCINE CANDIDATE ?DYAI-100? AND C1 TECHNOLOGY FOR PROTEIN-BASED CORONAVIRUS VACCINES AND THERAPEUTICS ? Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic?s C1 technology for the
August 11, 2021	EX-10.1	Press Release Dated August 10, 2021 Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful to the registrant if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. TERM SHEET FOR INTELLECTUAL PROPERTY LICENSE AGREEMENT This Term Sheet outlines the terms a
July 27, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) -12-31 FY 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000
July 27, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
July 27, 2021	EX-10.2	VLP sale agreement dated July 26, 2021 Exhibit 10.2 COMPRAVENTA DE PARTICIPACIONES SOCIALES DE LA SOCIEDAD ?VLP THE VACCINES COMPANY, S.L.?.- N?MERO TRES MIL CUATROCIENTOS QUINCE.- En Madrid, a veintis?is de julio de dos mil veintiuno.- ANTE M?, IGNACIO MARTINEZ-GIL VICH, Notario de Madrid, - COMPARECEN: - - De una parte: - DON ADRI?N MACHO CURIEL, mayor de edad, de nacionalidad espa?ola, soltero, analista de inversiones, con domicilio
July 27, 2021	EX-99.1	DYADIC ANNOUNCES TECHNOLOGY TRANSFER AND LICENSING AGREEMENT WITH SOUTH AFRICA’S RUBIC CONSORTIUM AIMING TO DEVELOP AND COMMERCIALIZE VACCINES FOR DISTRIBUTION THROUGHOUT THE AFRICAN CONTINENT POTENTIAL FOR AFFORDABLE COVID-19 IMMUNIZATION COVERAGE I Exhibit 99.1 DYADIC ANNOUNCES TECHNOLOGY TRANSFER AND LICENSING AGREEMENT WITH SOUTH AFRICA?S RUBIC CONSORTIUM AIMING TO DEVELOP AND COMMERCIALIZE VACCINES FOR DISTRIBUTION THROUGHOUT THE AFRICAN CONTINENT POTENTIAL FOR AFFORDABLE COVID-19 IMMUNIZATION COVERAGE IN UNDERSERVED AFRICAN COUNTRIES ? Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement ? Provides potenti
July 27, 2021	EX-10.1	BDI sale agreement dated July 26, 2021 Exhibit 10.1 COMPRAVENTA DE PARTICIPACIONES SOCIALES DE LA SOCIEDAD ?BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.?. N?MERO TRES MIL CUATROCIENTOS CATORCE.- En Madrid, a veintis?is de julio de dos mil veintiuno.- ANTE M?, IGNACIO MARTINEZ-GIL VICH, Notario de Madrid, - COMPARECEN: - -De una parte: - DON PABLO GUTIERREZ G?MEZ, mayor de edad, de nacionalidad espa?ola, ingeniero qu?mico, con domicili
July 27, 2021	EX-10.3	Amendment No. 1 dated July 26, 2021 to the Service Framework Agreement dated June 30, 2017 Exhibit 10.3 AMENDMENT N?1 TO THE SERVICE FRAMEWORK AGREEMENT This AMENDMENT N?1 TO THE SERVICE FRAMEWORK AGREEMENT (this ?Agreement?), signed as of July 26, 2021, is entered into by and between DYADIC INTERNATIONAL, INC., a Delaware corporation with headquarters located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-5094 USA and U.S. tax identification number 45-04867472 (?Dy
July 27, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 27, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
June 14, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 11, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
June 3, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : May 28, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
June 3, 2021	EX-10.1	Master Services Agreement and Work Order, between Dyadic International (USA), Inc. and CR2O B.V., Dated May 28, 2021. Specific items in this exhibit have been redacted, as market by three asterisks[*]. Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[*]?. CR2O.2021.DYADIC MSA063WO1 (#8057) Master Services Agreement Between Dyadic International (USA), Inc. and CR2O Master Services Ag
May 13, 2021	EX-99.1	DYADIC REPORTS 2021 FIRST QUARTER END RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC REPORTS 2021 FIRST QUARTER END RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS ? Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial o Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and ther
May 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 13, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
April 27, 2021	EX-10.1	Dyadic International, Inc. 2021 Equity Incentive Award Plan Exhibit 10.1 Appendix A DYADIC INTERNATIONAL, INC. 2021 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Dyadic International, Inc. 2021 Equity Incentive Award Plan (the ?Plan?) is to promote the success and enhance the value of Dyadic International, Inc. (the ?Company?) by linking the personal interests of the members of the Board, Employees, and Consultants to those of Company s
April 27, 2021	DEF 14A	- FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
April 27, 2021	DEFA14A	- FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
March 30, 2021	EX-99.1	DYADIC REPORTS 2020 YEAR END RESULTS AND RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC REPORTS 2020 YEAR END RESULTS AND RECENT COMPANY PROGRESS • Advancing Dyadic’s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial • To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization • To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates • Expande
March 30, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 30, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 30, 2021	EX-10.111	Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated August 13, 2020 Exhibit 10.11.1 INTRACOASTAL POINTE OFFICE BUILDING AMENDMENT TO OFFICE LEASE This Amendment to Office Lease Agreement made and entered in to this 13th day of August, 2020 by and between Quentin Partners Co. as Agent for Intracoastal Pointe, Inc. (both Florida corporations), as "Landlord;" and Dyadic International, Inc., as "Tenant." WITNESSETH WHEREAS, Landlord and Tenant entered into that Office
March 30, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 18, 2021	EX-99.1	Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 Exhibit 99.1 Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 ? Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from C1-cells ? DYAI-100 generated high levels of neutralizing antibodies in preclinical studies in mice,
March 18, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : March 18, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
March 18, 2021	EX-10.1	Master Services Agreement and Work Order, between Dyadic International (USA), Inc. and CR2O B.V., Dated March 18, 2021. Specific items in this exhibit have been redacted, as market by three asterisks[*] Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[*]?. Master Services Agreement First Stage Between Dyadic International and CR2O Master Services Agreement This First Stage of an anti
February 18, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : February 16, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264
February 18, 2021	EX-99.1	Dyadic International Presentation Exhibit 99.1
January 11, 2021	EX-99.1	DYADIC INTERNATIONAL APPOINTS NEW BOARD MEMBER DYADIC INTERNATIONAL APPOINTS NEW BOARD MEMBER JUPITER, FL – January 11, 2021 Dyadic International, Inc.
January 11, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : January 8, 2021 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
November 12, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC I
November 12, 2020	EX-99.1	DYADIC ANNOUNCES THIRD QUARTER 2020 RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC ANNOUNCES THIRD QUARTER 2020 RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS •Six new and expanded animal and human health collaborations since Q2 2020 •Expanded presence in the Asia Pacific Region •Important progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs •ZAPI to conduct additional animal studies for Schmallenberg Virus (SBV) and initiate a
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
October 13, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : October 12, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
October 13, 2020	EX-99	Dyadic Updates Market on COVID-19 Initiatives Dyadic Updates Market on COVID-19 Initiatives ■C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved ■Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators ■Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) ■Non-Exclusive Technology Usage Agreement with Epygen Biotech of India JUPITER, FL / ACCESSWIRE / October 12, 2020 Dyadic International, Inc.
August 21, 2020	CORRESP	- Dyadic International, Inc. 140 Intracoastal Pointe Drive Suite 404 Jupiter, Florida 33477 August 21, 2020 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Dyadic International, Inc. Registration Statement on Form S-3 (Registration No. 333-245687) Ladies and Gentlemen: In a
August 13, 2020	S-3	Description of Securities As filed with the Securities and Exchange Commission on August 13, 2020 Registration No.
August 13, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTERN
August 13, 2020	EX-1.2	Open Market Sale Agreement by and between the Company and Jeffries LLC, dated August 13, 2020 OPEN MARKET SALE AGREEMENTSM August 13, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Dyadic International, Inc.
August 13, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 13, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Co
August 13, 2020	EX-99.1	DYADIC ANNOUNCES SECOND QUARTER 2020 RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2020 RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS •Entered into two new collaborations with top tier animal health companies •Entered into a fully funded human health collaboration with a top five global pharmaceutical company •Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to be
July 1, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 29, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
June 29, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) : June 24, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
June 29, 2020	EX-10.1	Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020 Execution Version Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.
May 14, 2020	EX-99.1	DYADIC REPORTS 2020FIRST QUARTER RESULTS AND RECENT DEVELOPMENTS Exhibit 99.1 DYADIC REPORTS 2020FIRST QUARTER RESULTS AND RECENT DEVELOPMENTS •Two fully funded research projects with top four animal health companies. •Nonexclusive research license agreement with WuXi Biologics. •Feasibility study with the University of Oslo on influenza vaccine. •Engineered C1 cell lines to produce high levels of potential SARS-CoV-2 vaccines. •Strategic R&D relationships to a
May 14, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Commi
May 14, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55264 DYADIC INTER
May 13, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
May 12, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
March 30, 2020	EX-4.2	Description of Registered Securities Exhibit 4.2 DESCRIPTION OF SECURITIES References to the “Company”, “our”, or “us” herein are, unless the context otherwise indicates, only to Dyadic International, Inc. and not to any of its subsidiaries. Description of Capital Stock General The following is a summary of information concerning capital stock of the Company. The summaries and descriptions below do not purport to be complete statemen
March 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 30, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Com
March 30, 2020	EX-10.11	Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated June 21, 2019 exhibit1011jupiterlease2
March 30, 2020	EX-99.1	DYADIC REPORTS 2019 YEAR END RESULTS AND RECENT DEVELOPMENTS Exhibit 99.1 DYADIC REPORTS 2019 YEAR END RESULTS AND RECENT DEVELOPMENTS •New research license agreement with WuXi Biologics, a leading global CDMO •Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company •Six funded research collaborations and one expanded collaboration signed in 2019
March 30, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (
March 18, 2020	EX-99.1	Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress JUPITER, FLORIDA / ACCESSWIRE / March 18, 2020 - Dyadic International, Inc.
March 18, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported):March 17, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (Comm
March 18, 2020	EX-99.2	The C1 Technology Platform Making Healthcare Accessible & Affordable NASDAQ: DYAI Investor Presentation – March 2020 Safe Harbor Regarding Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements wit dyadicinvestorpresentati The C1 Technology Platform Making Healthcare Accessible & Affordable NASDAQ: DYAI Investor Presentation – March 2020 Safe Harbor Regarding Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance.
February 25, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
February 25, 2020	EX-99.1	Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Nes – Ziona, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc.
February 24, 2020	EX-99.1	DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED –Further Extends Company’s Biologic Market Opportunities – DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED –Further Extends Company’s Biologic Market Opportunities – JUPITER, FL / ACCESSWIRE / February 21, 2020 Dyadic International, Inc.
February 24, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 19, 2020 Dyadic Internat UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 19, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (
February 14, 2020	SC 13G/A	DYAI / Dyadic International, Inc. / KITT BARRY M - FORM SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
January 28, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2020 Dyadic International, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-55264 (C
January 28, 2020	EX-99.1	Dyadic to Interview with FOX Business Network on Monday, January 27, 2020 Dyadic to Interview with FOX Business Network on Monday, January 27, 2020 JUPITER, FLORIDA / ACCESSWIRE / January 27, 2020 - Dyadic International, Inc.
January 28, 2020	EX-99.2	Dyadic Interviewed with FOX Business Network Dyadic Interviewed with FOX Business Network JUPITER, FLORIDA / ACCESSWIRE / January 28, 2020 - Dyadic International, Inc.

DYAI / Dyadic International, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)